Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

Ezra Cohen, MD
Published: Tuesday, Jul 18, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

The future of immunotherapy in head and neck cancer lies in combinations, says Cohen.

With the approved agents pembrolizumab (Keytruda) and nivolumab (Opdivo), as well as durvalumab (Imfinzi) and avelumab (Bavencio)—which have both shown single-agent activity—the question that remains is how these combinations will fit into the standard of care.
 


Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

The future of immunotherapy in head and neck cancer lies in combinations, says Cohen.

With the approved agents pembrolizumab (Keytruda) and nivolumab (Opdivo), as well as durvalumab (Imfinzi) and avelumab (Bavencio)—which have both shown single-agent activity—the question that remains is how these combinations will fit into the standard of care.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x